Imatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-IMATINIB |
|---|---|
| Type | Drug |
| Aliases | GleevecGlivecimatinib genericІматиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CML DIS-GIST DIS-MELANOMA |
| Sources | SRC-ELN-CML-2020 SRC-IRIS-OBRIEN-2003 SRC-NCCN-MPN-2025 |
Drug Facts
| Class | BCR-ABL1 / KIT / PDGFR tyrosine-kinase inhibitor (1st-generation) |
|---|---|
| Mechanism | Selective TKI of BCR-ABL1, KIT, PDGFR-α/β. Founder of the targeted CML era. Standard CML 1L for low-risk, comorbid, or cost-constrained patients. |
| Typical dosing | CML chronic phase: 400 mg PO once daily with food + large glass of water. Ph+ ALL: 600-800 mg daily. Take with meal to reduce GI toxicity. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Standard 1L for low-risk Sokal/EUTOS CML, elderly, or in cost-constrained settings (generics widely available, НСЗУ-reimbursed in Ukraine). 2nd-gen TKIs (dasatinib, nilotinib, bosutinib) achieve faster deep molecular response but no consistent OS benefit — ELN 2020 leaves choice to comorbidity matrix. Take with food + water.
Used By
Regimens
REG-IMATINIB-CML- Imatinib (CML chronic phase 1L)REG-IMATINIB-GIST-1L- Imatinib (GIST advanced/metastatic 1L; KIT/PDGFRA imatinib-sensitive)REG-IMATINIB-KIT-MELANOMA- Imatinib (KIT-mutant mucosal/acral melanoma)